S-1/A: ENDRA Life Sciences Eyes $8 Million Raise Through Stock and Warrant Offering

ENDRA Life Sciences is seeking to raise capital through a public offering of common stock, pre-funded warrants, and common stock purchase warrants.

Summary

• ENDRA Life Sciences is planning a public offering to sell up to 29,962,546 shares of common stock, along with Series A and Series B warrants to purchase an equal number of shares.
• The company is also offering pre-funded warrants to purchase up to 29,962,546 shares of common stock as an alternative to common stock for certain investors.
• Each share of common stock or pre-funded warrant will be sold with one Series A warrant and one Series B warrant.
• The Series A warrants will be exercisable at a price of $[] per share after shareholder approval and charter amendment effectiveness, expiring five years from the initial exercise date.
• The Series B warrants will be exercisable at a price of $[] per share beginning on the initial exercise date and expiring two and a half years later, with an alternative cashless exercise option.
• The assumed public offering price is $0.267 per share and accompanying warrants, but the actual price will be determined at the time of pricing.
• Craig-Hallum Capital Group LLC is acting as the exclusive placement agent for the offering, receiving a fee of 7.0% of the gross proceeds and warrants to purchase 5.0% of the common stock in the offering.
• ENDRA estimates net proceeds of approximately $7.1 million from the offering, which will be used for working capital and general corporate purposes.
• The company's stock is subject to minimum bid price requirements for continued listing on the Nasdaq Capital Market, and a reverse stock split may be considered to regain compliance.

Sentiment

Score: 4

Explanation: The document is largely factual, outlining the terms of the offering. However, the company's financial situation and the risks associated with the investment temper the sentiment.

Positives

• The offering provides ENDRA with additional capital to fund its operations and pursue its business strategy.
• The inclusion of warrants may make the offering more attractive to investors.
• The company has the flexibility to use pre-funded warrants in place of common stock for certain investors.
• The company has the option to reduce the exercise price of the warrants.
• The company has the option to redeem the warrants.

Negatives

• The company has a history of operating losses and will need to raise significant additional capital to continue its business and operations.
• The company's stock price has fluctuated in the past, has recently been volatile and may be volatile in the future for reasons unrelated to our operating performance or prospects, and as a result, investors in our common stock could incur substantial losses.
• The company's stock is subject to minimum requirements to remain listed on the Nasdaq Capital Market, including a minimum bid price requirement, and may be delisted if it does not maintain compliance with those requirements.
• There is no public market for the warrants.
• The warrants are not exercisable until shareholder approval and, in certain cases, may be redeemed by the Company prior to their expiration.
• If the Series B Warrants are exercised by way of an alternative cashless exercise, investors may suffer substantial dilution.
• We may not receive any additional funds upon the exercise of the Series B Warrants.
• The common warrants in this offering are speculative in nature.

Risks

• ENDRA has a history of operating losses and needs additional capital.
• The company's stock price is volatile and may decline.
• Failure to maintain Nasdaq listing requirements could result in delisting.
• There is no established public market for the warrants.
• The company may not raise the amount of capital it believes is required for its business plans, including its near-term business plans.
• The company's management will have broad discretion over the use of the net proceeds from this offering, which we may not use effectively or in a manner with which you agree.
• The warrants are not exercisable until shareholder approval and, in certain cases, may be redeemed by the Company prior to their expiration.
• If the Series B Warrants are exercised by way of an alternative cashless exercise, investors may suffer substantial dilution.
• We may not receive any additional funds upon the exercise of the Series B Warrants.
• The common warrants in this offering are speculative in nature.

Future Outlook

ENDRA intends to use the net proceeds from this offering for working capital and general corporate purposes and anticipates completing the necessary clinical studies by the fourth quarter of 2024 or first quarter of 2025 and submitting the new de novo request to the FDA in the first half of 2025.

Industry Context

The global diagnostic ultrasound device market is anticipated to expand at a CAGR of 4.07% from 2022 to 2030, according to Grand View Research. ENDRA is positioning its TAEUS technology to enhance existing ultrasound systems and compete with more expensive imaging technologies like CT and MRI.

Comparison to Industry Standards

• CT systems can cost approximately $1 million and an MRI system can cost up to approximately $3 million.
• Smaller portable ultrasound systems can cost as little as approximately $5,000 and the price of new cart-based ultrasound systems can range from approximately $75,000 to $200,000.
• ENDRA intends to price its initial liver TAEUS system at a price point of approximately $65,000.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• The offering could provide the company with the financial resources to continue its operations and develop its technology, potentially benefiting stakeholders in the long term.

Next Steps

• Obtain shareholder approval for the issuance of shares upon exercise of the warrants.
• File the Charter Amendment with the Secretary of State of the State of Delaware.
• Complete necessary clinical studies.
• Submit the new de novo request to the FDA.

Key Dates

Keywords

warrants, offering, common stock, ENDRA, capital raise, pre-funded warrants, shareholder approval, dilution, Nasdaq, Craig-Hallum